Date: 06/05/2019

To,
National Stock Exchange of India Ltd.  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai- 400 051  
Tel No: (022) 26598100 - 8114  
Fax No: (022) 26598120  
Symbol: MOREPENLAB

BSE Limited
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai- 400 001  
Phones: 91-22-22721233/4  
Fax: 91-22-22723121  
Scrip Code: 500288

Subject: Intimation of Post Results (Q4 of FY 2018-19) Conference Call

Dear Sir,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform you that subsequent to the declaration of Audited Financial Results for the quarter and year ended 31st March, 2019, the Company is organizing an ‘Investor and Analyst Conference Call’ on Wednesday, 8th May, 2019 at 4.00 P.M. (IST).

The details of the conference call are attached herewith.

This is for your information and records.

Thanking you.

Yours faithfully,

For Morepen Laboratories Limited

(Vipul Kumar Srivastava)
Company Secretary

Encl.: As Above
Morepen Laboratories Ltd. is one of India's leading API & Health Care diagnostics manufacturer. The company will be hosting a conference call for investors and analyst community on **Wednesday, 8th May, 2019 at 04.00 P.M. (IST)**

The call will be initiated with a brief management discussion on the company, business segments and earnings performance followed by an interactive question and answer session.

On behalf of the company the call will addressed by:

- **Mr Sushil Suri : Chairman and Managing Director**
- **Mr Ajay Sharma : Chief Financial Officer**

**Details of the conference call are as follows:**

**Wednesday, 8th May 2019 – 04.00 P.M. (IST)**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mumbai (Primary No.)</td>
<td>+91 22- 62801239</td>
</tr>
<tr>
<td>Universal Access</td>
<td>022- 7115 8140</td>
</tr>
<tr>
<td>USA</td>
<td>18667462133</td>
</tr>
<tr>
<td>UK</td>
<td>08081011573</td>
</tr>
<tr>
<td>Singapore</td>
<td>8001012045</td>
</tr>
<tr>
<td>Hong Kong</td>
<td>800964448</td>
</tr>
</tbody>
</table>

**Note:** When using dial-in numbers mentioned below please do so 10 minutes prior to the conference schedule to ensure that you are connected to your call in time.

===================================================================================================

**About Morepen Laboratories Limited**

Morepen Laboratories Ltd. (Morepen) is a 35-year old, around Rs. 800 Cr. pharmaceutical and healthcare products company. The company went public in the year 1993 and is currently listed at both the Bombay Stock Exchange as well as the National Stock Exchange.

Morepen is engaged in the manufacturing and sale of APIs/ Bulk Drugs, Home Diagnostics, Formulations and OTC products. The company's state-of-the-art manufacturing facility at Baddi (Himachal Pradesh) comprises a scientifically integrated complex of 10 plants, each with a specific product profile.

The USFDA approved plant at Masulkhana is for manufacture of Loratadine, an antiallergy drug - internationally known as Claritin. Desloratadine and the new blockbuster drug Montelukast is also manufactured at this FDA approved site. The large and spread out manufacturing facility at Baddi has EU GMP & WHO GMP Standards and manufactures latest and much in demand APIs like
Atorvastatin, Rosuvastatin, Fexofenadine and others for regulated markets of Europe, USA and also for non-regulated markets across the globe.

Morepen markets over 100 branded formulations under six major therapeutic segments in the domestic market. The company's manufacturing facilities are backed by a strong dedicated team of research and development (R&D) professionals who ensure stringent quality standards. In Home-Diagnostics business, Morepen has a formidable presence in Blood Glucose Monitors and Blood Pressure Monitors, in the domestic markets. The company's OTC brands are being promoted under its wholly owned subsidiary Dr. Morepen Limited. Dr. Morepen's famous OTC product line, including Burnol, Lemolate, Sat-Isabgol, Pain-X and others, has a significant presence in the domestic market.

For any further information please contact

Mr. Sonal Kumar Shrivastava
Kirin Advisors
Ph -9324748334
Email: sonalkumar@kirinadvisors.com

DISCLAIMER:
Certain statements that may be made or discussed at the conference call may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and abroad. Actual results might differ substantially from those expressed or implied. Morepen Laboratories Ltd and its Management will not be in any way responsible for any action taken based on such statements and discussions. Morepen also undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.